for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Heron Therapeutics Inc

HRTX.OQ

Latest Trade

25.67USD

Change

-0.02(-0.08%)

Volume

104,659

Today's Range

25.39

 - 

25.89

52 Week Range

15.68

 - 

28.69

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
25.69
Open
25.68
Volume
104,659
3M AVG Volume
23.51
Today's High
25.89
Today's Low
25.39
52 Week High
28.69
52 Week Low
15.68
Shares Out (MIL)
88.35
Market Cap (MIL)
2,307.12
Forward P/E
-10.31
Dividend (Yield %)
--

Latest Developments

More

Heron Therapeutics Reports Qtrly Net Loss Of $0.42 Per Share

Heron Therapeutics Announces FDA Acceptance Of New Drug Application Resubmission For HTX-011 For Management Of Postoperative Pain

Heron Announces FDA Approval Of Supplemental New Drug Application To Expand Cinvanti® Label For Single-Dose Regimen For Patients Receiving Moderately Emetogenic Chemotherapy

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Heron Therapeutics Inc

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

Industry

Major Drugs

Contact Info

4242 Campus Point Ct Ste 200

+1.858.2514400

http://www.herontx.com/

Executive Leadership

Kevin C. Tang

Independent Chairman of the Board

Barry D. Quart

President, Chief Executive Officer, Director

Robert E. Hoffman

Chief Financial Officer, Senior Vice President - Finance

David L. Szekeres

Senior Vice President, General Counsel, Business Development, Corporate Secretary

Anita Gupta

Senior Vice President - Medical Strategy and Government Affairs

Key Stats

1.60 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-4.560

2017

-3.650

2018

-2.440

2019(E)

-2.468
Price To Earnings (TTM)
--
Price To Sales (TTM)
16.51
Price To Book (MRQ)
8.08
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.88
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-55.87
Return on Equity (TTM)
-45.47

Latest News

Latest News

BRIEF-Heron Therapeutics Reports Quarterly Loss Per Share Of $0.81

* HERON THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2018 AND RECENT CORPORATE PROGRESS

BRIEF-Heron Therapeutics Announces Pricing Of Underwritten Public Offering

* HERON THERAPEUTICS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

BRIEF-Heron Therapeutics Announces Proposed Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Heron Announces Positive Topline Results From Pivotal Phase 3 Clinical Trials Of HTX-011 In Bunionectomy And Hernia Repair

* HERON ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIALS OF HTX-011 IN BUNIONECTOMY AND HERNIA REPAIR

BRIEF-Heron Therapeutics Qtrly Net Loss Per Share $1.09

* HERON THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2017 AND RECENT CORPORATE PROGRESS

BRIEF-Heron Therapeutics Announces Pricing Of Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Heron Therapeutics Announces Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

BUZZ-Heron Therapeutics: FDA approves chemotherapy-induced nausea drug

** Drug developer's shares rise 4.9 pct to $18.20 after market

BRIEF-Heron Therapeutics gets FDA approval for Cinvanti

* Announces U.S. FDA approval of Cinvanti™ (aprepitant) injectable emulsion for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (cinv)

BRIEF-Heron Therapeutics reports qtrly diluted net loss per share $0.77

* Heron Therapeutics reports financial results for the three and nine months ended September 30, 2017 and recent corporate progress

BRIEF-Heron Therapeutics granted FDA fast track designation for HTX-011

* Heron Therapeutics granted FDA fast track designation for HTX-011 to reduce postoperative pain and the need for opioid analgesics for 72 hours

BRIEF-Heron Therapeutics initiates phase 3 program for HTX-011

* Heron Therapeutics announces initiation of phase 3 program for HTX-011 in postoperative pain following successful end-of-phase 2 meeting with FDA

BRIEF-Heron Therapeutics reports quarterly loss per share $0.80

* Heron Therapeutics reports financial results for the three and six months ended June 30, 2017 and recent corporate progress

BRIEF-Heron Therapeutics reports quarterly loss per share $1.00

* Heron Therapeutics reports financial results for the three months ended March 31, 2017 and recent corporate progress

BRIEF-Heron Therapeutics appoints Robert Hoffman as CFO

* Heron Therapeutics appoints Robert E. Hoffman as chief financial officer and senior vice president, finance

BRIEF-Heron Therapeutics announces inclusion of sustol extended-release injection in NCCN antiemesis guidelines

* Heron Therapeutics Inc - Announces inclusion of sustol extended-release injection in nccn antiemesis guidelines Source text for Eikon: Further company coverage:

BRIEF-Heron Therapeutics files pricing term sheet related to its common stock offering

* Files pricing term sheet related to its common stock offering - sec filing

BRIEF-Heron Therapeutics files for common stock offering of up to $150 ml

* Files for common stock offering of up to $150 million - SEC filing Source text: (http://bit.ly/2iSyoxH) Further company coverage:

Heron drug for post-surgery pain succeeds in midstage trial

Heron Therapeutics Inc on Wednesday said its experimental combination drug for post-operative pain led to significant reductions in pain intensity and the need for opioids, according to initial data from a midstage trial.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up